GlassScriptPhysician profile
Tyler J Saunders
NPI 1174018899
$2,099.28
in general payments reported to CMS, 2019-2025
21 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.94 · 2021: $40.13 · 2022: $372 · 2023: $743 · 2024: $740 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $695.20 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $333.09 | 2023-2024 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $289.42 | 2023-2024 | |
| Pfizer INC. | $222.33 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $60.76 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Viiv Healthcare Company | $53.90 | 2023-2024 | Apretude |
| Inspire Medical Systems, INC. | $50.08 | 2023-2025 | Inspire |
| Exact Sciences Corporation | $49.84 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $45.11 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $41.29 | 2023-2024 | Mounjaro, Zepbound |
| Abbott Laboratories | $36.42 | 2022-2023 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $35.99 | 2023-2024 | Tirosint, Licart, Tirosint |
| Phathom Pharmaceuticals, INC. | $35.04 | 2024-2025 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $26.72 | 2024 | Opsumit, Uptravi |
| Xeris Pharmaceuticals, INC. | $21.45 | 2023 | Keveyis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19.37 | 2023 | Farxiga |
| Abbvie INC. | $19.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.43 | 2021 | |
| Currax Pharmaceuticals LLC | $16.82 | 2023 | Contrave |
| Genentech USA, INC. | $14.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.08 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.